| Autor: |
Chang, Bill H., Leonard, Jessica, Wolf, Joelle, Degnin, Michelle, Lenz, Kyle, Wilmot, Beth, Mullighan, Charles G., Loh, Mignon L., Hunger, Stephen P., Tyner, Jeffrey W., Druker, Brian J. |
| Zdroj: |
Blood; November 2018, Vol. 132 Issue: 1, Number 1 Supplement 1 p4026-4026, 1p |
| Abstrakt: |
Acute Lymphoblastic Leukemia (ALL) harboring the t(17;19)(q22;p13) is a rare subtype of leukemia with a dismal prognosis. This recurring translocation produces an aberrant TCF3-HLFfusion with distinct gene expression profiles and drug sensitivity. Recent studies have shown that this subtype of ALL might be targeted using therapies inhibiting BCL-2 and the pre-B cell receptor through inhibition of SRC family kinases. However, preliminary validation of these studies have revealed significant heterogeneity of response to BCL-2 and SRC inhibitors. As such, we sought to identify other possible targets that could overcome this heterogeneity and improve response to therapy. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
